New cell therapy aims to control High-Risk blood cancers after transplant
NCT ID NCT07285668
First seen Jan 05, 2026 · Last updated May 15, 2026 · Updated 19 times
Summary
This study tests a special type of donor cell infusion (called TCRαβ+/CD19+ depleted DLI) given after a stem cell transplant to help control high-risk blood cancers like leukemia. The goal is to find a safe dose and see if it reduces side effects like graft-versus-host disease. About 38 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UW Carbone Cancer Center
Madison, Wisconsin, 53792, United States
Conditions
Explore the condition pages connected to this study.